mProX™ Human FGFR3 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- Kinase Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
Ronald
Verified Customer
Jason
Verified Customer
Any questions about our products? Please visit our frequently asked questions page.
Published Data
Fig.1 Phenotypic properties of PDAC cell lines.
The PDAC cell lines' FGFR3 expression was assessed using a western blot. In BxPC-3 cells, FGFR3 expression was highest, but in Mia PaCa-2 cells, it was lowest.
Ref: Lafitte, Marie, et al. "FGFR3 has tumor suppressor properties in cells with epithelial phenotype." Molecular cancer 12 (2013): 1-13.
Pubmed: 23902722
DOI: 10.1186/1476-4598-12-83
Research Highlights
Anti-FGFR3 medication would likely be more beneficial for patients with FGFR3 mutant tumors than for those whose cancers just overexpress the FGFR3 protein.
van Rhijn, Bas WG, et al. "FGFR3 mutation status and FGFR3 expression in a large bladder cancer cohort treated by radical cystectomy: implications for anti-FGFR3 treatment?." European Urology 78.5 (2020): 682-687.
Pubmed:
32682615
DOI:
10.1016/j.eururo.2020.07.002
Based on these findings, patients with oncogenic FGFR3 mutations, such as the FGFR3-TACC3 fusion, may benefit from targeting FGFR3 as a treatment strategy for TNBC.
Chew, Nicole J., et al. "FGFR3 signaling and function in triple negative breast cancer." Cell Communication and Signaling 18 (2020): 1-17.
Pubmed:
31987043
DOI:
10.1186/s12964-019-0486-4
